HSCS Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -108157.9% compared to HeartSciences, Inc.'s net margin of -269.38%. HeartSciences, Inc.'s return on equity of -290.66% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

HeartSciences, Inc. has a consensus price target of $10.50, signalling upside risk potential of 293.26%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1556.09%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than HeartSciences, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than HeartSciences, Inc..

HeartSciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HeartSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartSciences, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

HeartSciences, Inc. quarterly revenues are $1.9K, which are smaller than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. HeartSciences, Inc.'s net income of -$2.1M is higher than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, HeartSciences, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartSciences, Inc. is 457.79x versus 1.44x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -108157.9% compared to HeartSciences, Inc.'s net margin of -162.05%. HeartSciences, Inc.'s return on equity of -290.66% beat Standard BioTools, Inc.'s return on equity of -24.44%.

HeartSciences, Inc. has a consensus price target of $10.50, signalling upside risk potential of 293.26%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 8.39%. Given that HeartSciences, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe HeartSciences, Inc. is more attractive than Standard BioTools, Inc..

HeartSciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.

HeartSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartSciences, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

HeartSciences, Inc. quarterly revenues are $1.9K, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. HeartSciences, Inc.'s net income of -$2.1M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, HeartSciences, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartSciences, Inc. is 457.79x versus 4.21x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -108157.9% compared to HeartSciences, Inc.'s net margin of -25.94%. HeartSciences, Inc.'s return on equity of -290.66% beat LENSAR, Inc.'s return on equity of -1013.45%.

HeartSciences, Inc. has a consensus price target of $10.50, signalling upside risk potential of 293.26%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 33.93%. Given that HeartSciences, Inc. has higher upside potential than LENSAR, Inc., analysts believe HeartSciences, Inc. is more attractive than LENSAR, Inc..

HeartSciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.

HeartSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartSciences, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

HeartSciences, Inc. quarterly revenues are $1.9K, which are smaller than LENSAR, Inc. quarterly revenues of $14.3M. HeartSciences, Inc.'s net income of -$2.1M is higher than LENSAR, Inc.'s net income of -$3.7M. Notably, HeartSciences, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartSciences, Inc. is 457.79x versus 2.24x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Movano, Inc. has a net margin of -108157.9% compared to HeartSciences, Inc.'s net margin of -5036.25%. HeartSciences, Inc.'s return on equity of -290.66% beat Movano, Inc.'s return on equity of -410.28%.

HeartSciences, Inc. has a consensus price target of $10.50, signalling upside risk potential of 293.26%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3340.37%. Given that Movano, Inc. has higher upside potential than HeartSciences, Inc., analysts believe Movano, Inc. is more attractive than HeartSciences, Inc..

HeartSciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HeartSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartSciences, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

HeartSciences, Inc. quarterly revenues are $1.9K, which are smaller than Movano, Inc. quarterly revenues of $80K. HeartSciences, Inc.'s net income of -$2.1M is higher than Movano, Inc.'s net income of -$4M. Notably, HeartSciences, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartSciences, Inc. is 457.79x versus 13.20x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.